Page 1662 - Clinical Small Animal Internal Medicine

1600 Index

disseminated intravascular mitral and triscuspid diastolic chronic kidney disease 1172
VetBooks.ir liver disease 644 nonvalvular abnormal flows etiology/pathophysiology
clinical data on probiotics in
inflows 141–142, 147–149, 153,
coagulation (DIC) (cont’d)
veterinary medicine 625–626
158–159
pulmonary thromboembolism
316–317 149–151, 160 622–623, 623
septic shock 423, 426 normal transvalvular flows exocrine pancreatic
trauma and burns 445, 453–454 139–145, 152–154 insufficiency 583, 588, 622
yersiniosis 952 physiologic regurgitations healthy dogs and cats 621–622
distraction index (DI) 1540 144, 154 importance of gastrointestinal
distribution 10–12, 11–13 pulmonary and aortic systolic microbiota 621
distribution‐free tests 10 flows 141, 145–147, 152, inflammatory bowel disease
disuse osteoporosis 1527 155–156 621–622, 623, 624–625
diuretics pulsed‐wave and continuous‐wave probiotics, prebiotics, and
acute kidney injury 1095–1096 modes 138–139, 145 synbiotics 623–624
acute respiratory failure 388–389 quantitative measurements selection of probiotics 624–625
canine inflammatory liver 144–145, 159 therapeutic approach 623–625
disease 701 standard Doppler modes dysphagia
cardiogenic shock 417 138–139, 145 esophageal disorders 557
feline myocardial disease 273 Doppler gastrointestinal imaging 473–474
glomerular disease 1106 sphygmomanometry 221–222 neuromuscular junction
head trauma 756 double balloon enteroscopy 531–532 diseases 807
heart failure 186, 187, 192–196, 195 double‐contrast crystography dysphonia 807
magnesium homeostasis and 1134, 1135 dyspnea
disorders 1088 DPCTA see dual‐phase computed cardiovascular disease 120
pericardial disease 280 tomography angiography chest wall 294–295
urolithiasis 1138–1139 dried solidified blood calculi 1131 diaphragm 295
valvular heart disease 249 drug/drug metabolite urolithiasis 1132 feline bronchial asthma 297
diverticulum 505 drug‐induced neuromuscular initial approach and
DKA see diabetic ketoacidosis blockade 808 examination 289
DL see demyelinating drug‐induced lower airway 290–291
leukoencephalomyelitis osteoporosis 1527–1528 nonrespiratory causes 295
DLE see discoid lupus erythematosus drug‐induced tremors 770 pleural effusion 338
DM see degenerative myelopathy; drug metabolism and dosage 351 pleural space 291–292
dermatomyositis; diabetes drug toxicity pulmonary parenchyma
mellitus antifungal therapy 1049, 292–293, 293
DMOA see disease‐modifying 1051–1052 pulmonary
osteoarthritis agents antimicrobials 1041–1048, 1044 thromboembolism 293–294
DOAC see direct oral anticoagulants neuromuscular junction respiratory monitoring in critical
DOD see developmental orthopedic diseases 808 care 373, 375–376
diseases toxic diseases of the liver 683–684 respiratory pattern‐based
dopamine vestibular disease 792–794 approach 289–296
acute kidney injury 1098 dual‐energy X‐ray absorptiometry surgical approaches to thoracic
heart failure 196 (DEXA/DXA) 1523–1524 disease 329
neuroendocrinology 41 dual‐phase computed tomography upper airway 289–290, 290
pituitary‐dependent angiography (DPCTA) 716, dysregulated immunity 422
hyperadrenocorticism 50–51 718, 720 dystrophic mineralization
supraventricular arrhythmias 212 DUD see detrusor urethral dyssynergy 661–663, 662
dopaminergic D2 antagonists 575, duodenograstric reflux 567
579–580 duodenoscopy 520–522, 521–522 e
Doppler echocardiography 137–151 duodenum 487, 488 ear canal tumors 1355–1356
advanced ultrasound techniques DXA see dual‐energy X‐ray ear clean solutions 1398–1399,
152, 161 absorptiometry 1474–1475, 1476, 1478
basic principles 138 dysautonomia 570, 828, 1188 EBA see epidermolysis bullosa acquisita
color flow mode 139 dysbiosis 621–626 EBC see exhaled breath condensate
common abnormal flow antibiotics 625 Ebola virus 901–902
patterns 145–151, 155–160 chronic enteropathies 628–629 clinical signs 902